Mohan C R, Hoballah J J, Sharp W J, Kresowik T F, Lu C T, Corson J D
Section of Vascular Surgery, University of Iowa Hospitals & Clinics, Iowa City 52242.
J Vasc Surg. 1995 Feb;21(2):235-45; discussion 245-6. doi: 10.1016/s0741-5214(95)70265-2.
A variety of vena caval filters (VCFs) are available for usage. The choice of filter type depends on physician preference and certain patient variables. An evaluation of the different VCFs used in our institution was done to compare their efficacy and complication rates.
The medical records of all patients who underwent insertion of a VCF from January 1987 to June 1993 at the University of Iowa Hospitals & Clinics and the affiliated Veterans Administration Medical Center were reviewed. One hundred ninety-nine VCFs were placed in 196 patients (123 males, 73 females), with a mean age of 61 years (range 13 to 87 years). Thirty-five (18%) VCFs (30 stainless steel Greenfield filters [SGFs] and five titanium Greenfield filters with modified hook [TGF-MHs]) were inserted in the operating room via an open technique. The remaining 164 VCFs (82%) were inserted in the radiology suite by a percutaneous technique (38 SGF, 23 TGF-MH, 51 Vena Tech filters [VTFs], 48 Bird's nest filters [BNFs] and 4 Simon Nitinol filters). Thromboembolic risk factors in these 196 patients included malignancy (99), trauma (21), recent surgery (27), cerebrovascular accident with paralysis (6), and miscellaneous conditions (43). Indications for VCF placement included a contraindication to anticoagulation (92), complication of anticoagulation (44), failure of anticoagulation (26), prophylaxis (31), adjunct to pulmonary embolectomy (1), noncompliance (1), hemodynamically unstable patient (1), and prior VCF complication (3). Mean follow-up of the patients was 12 months (range 0 to 87 months). Because there were only four Simon Nitinol filters inserted during the study period, they were excluded from further analysis.
A comparative analysis revealed that there was a significantly higher incidence of symptomatic IVC thrombosis with the use of the BNF (n = 7) (14.6%) versus the SGF (n = 0) (0%), TGF-MH (n = 1) (3.6%), or VTF (n = 2) (4%) (p < 0.05 by chi-squared testing). The VCF-related mortality rate was also higher with the BNF (n = 5) (10.9%) versus the SGF (n = 1) (1.5%), TGF-MH (n = 1) (3.6%), or VTF (n = 0) (0%) (p < 0.05 by chi-squared testing). However there was no significant difference in the occurrence of clinically apparent recurrent pulmonary embolism during follow-up between the four different filter types (2 [4.2%] BNF, 3 [4.4%] SGF, 1 [3.6%] TGF-MH, and 1 [2%] VTF).
These data indicate that the use of the BNF was associated with increased morbidity and mortality rates compared with the use of the SGF, TGF-MH, and VTF filters.
有多种腔静脉滤器(VCF)可供使用。滤器类型的选择取决于医生的偏好和某些患者变量。我们对本机构使用的不同VCF进行了评估,以比较它们的疗效和并发症发生率。
回顾了1987年1月至1993年6月在爱荷华大学医院及诊所和附属退伍军人管理局医疗中心接受VCF植入的所有患者的病历。199个VCF被植入196例患者(123例男性,73例女性),平均年龄61岁(范围13至87岁)。35个(18%)VCF(30个不锈钢Greenfield滤器[SGF]和5个带改良钩的钛制Greenfield滤器[TGF-MH])通过开放技术在手术室植入。其余164个VCF(82%)通过经皮技术在放射科植入(38个SGF,23个TGF-MH,51个Vena Tech滤器[VTF],48个鸟巢式滤器[BNF]和4个西蒙镍钛合金滤器)。这196例患者的血栓栓塞危险因素包括恶性肿瘤(99例)、创伤(21例)、近期手术(27例)、伴有瘫痪的脑血管意外(6例)和其他情况(43例)。VCF植入的指征包括抗凝禁忌(92例)、抗凝并发症(44例)、抗凝失败(26例)、预防(31例)、肺栓子切除术辅助(1例)、不依从(1例)、血流动力学不稳定患者(1例)和既往VCF并发症(3例)。患者的平均随访时间为12个月(范围0至87个月)。由于研究期间仅植入了4个西蒙镍钛合金滤器,因此将它们排除在进一步分析之外。
一项比较分析显示,与SGF(n = 0)(0%)、TGF-MH(n = 1)(3.6%)或VTF(n = 2)(4%)相比,使用BNF( n = 7)(14.6%)时,症状性下腔静脉血栓形成的发生率显著更高(卡方检验,p < 0.05)。与SGF(n = 1)(1.5%)、TGF-MH(n = 1)(3.6%)或VTF(n = 0)(0%)相比,BNF(n = 5)(10.9%)的VCF相关死亡率也更高(卡方检验,p < 0.05)。然而,在随访期间,四种不同滤器类型之间临床明显复发性肺栓塞的发生率没有显著差异(2例[4.2%]BNF,3例[4.4%]SGF,1例[3.6%]TGF-MH,1例[2%]VTF)。
这些数据表明,与使用SGF、TGF-MH和VTF滤器相比,使用BNF会增加发病率和死亡率。